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ABSTRACT 
Human papillomavirus (HPV) is the major cause of cervical cancer. The well-established 
natural history from HPV infection to the occurrence of invasive cervical cancer serves as the 
basis for prevention of cervical cancer through prophylactic HPV vaccination (primary 
prevention) and cervical screening (secondary prevention). Cervical cancer detected through 
screening also has better chances of being cured than cancers not detected through screening. 
This thesis addresses research questions on prevention and prognosis of cervical cancer within 
the framework of the interplay of HPV, vaccination, and cervical screening, and it also provides 
insights for evidence-based decision-making. 
In Paper I, we examined the association between cervical screening with cytology and risk of 
adenosquamous cell carcinoma (ASC) and rare histological types of invasive cervical 
carcinoma (RICC). Based on a nationwide cervical cancer Audit, we conducted a nested case-
control study including 338 cases of ASC and RICC diagnosed during 2002-2011 in Sweden 
with their year-of-birth-matched controls. We found that screening with cytology was 
associated with decreased risk of ASC and RICC, but the magnitude of risk reduction in relation 
to cervical screening was less for RICC than for ASC. The majority of ASC and RICC cases 
were positive for high-risk HPV in tumor tissues. 
In Paper II, we evaluated whether the tumor high-risk human papillomavirus (hrHPV) status 
was associated with the prognosis of cervical cancer. In a nationwide population-based study, 
we included 2845 primary invasive cervical cancer cases diagnosed in Sweden during 2002–
2011, and comprehensively tested diagnostic blocks for 13 hrHPV types and 24 HPV types 
which were not established as oncogenic. Women with hrHPV-positive cervical tumors had a 
substantially better prognosis (39% lower excess mortality) than women with hrHPV-negative 
tumors. The difference of prognosis by tumor hrHPV status remained statistically significant, 
irrespective of age, cancer stage, and histological type.  
In Paper III, we investigated screening performance in terms of positive predictive value 
(PPV) of cytology for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) among HPV-
vaccinated birth cohorts. Using a population-based cohort design, we included women born 
1989-1993 who were resident in Sweden since the introduction of HPV vaccination and 
attended cervical screening at age 23, based on records from Swedish National Cervical 
Screening Registry (NKCx). We found that vaccinated women had lower PPV of cytology for 
CIN2+ compared to unvaccinated women. The decrease in PPV was greater among women 
vaccinated before age 17 than those vaccinated at age 17-22. 
In Paper IV, we assessed the association between HPV vaccination and the risk of invasive 
cervical cancer in a population-based cohort study. An open cohort of women aged 15-30 
(including age 30) living in Sweden were included and followed during 2006-2017 for HPV 
vaccination and first occurrence of invasive cervical cancer. The findings showed that HPV 
vaccination was related to a 52% lower risk of invasive cervical cancer for vaccinated women 
compared to unvaccinated women. Younger age at vaccination initiation was associated with 
a more pronounced risk reduction (83% risk reduction when vaccinated before age 17). 
In conclusion, this thesis shows that cervical screening can effectively reduce the risk of ASC 
and RICC, which is beyond the established evidence on preventing squamous cell carcinoma 
and adenocarcinoma. HPV vaccination can effectively reduce the risk of cervical cancer; the 
ultimate goal of cervical cancer prevention. With the implementation of HPV vaccination, the 
PPV of cytology for CIN2+ has decreased in vaccinated women compared to unvaccinated 
women, especially among those vaccinated at younger age. Tumor hrHPV status is associated 
with the prognosis of cervical cancer, which could add value to the clinically established 
prognostic factors. Taken together, these studies add knowledge to the current understanding 
of cervical cancer prevention strategies and prognosis of cervical cancer, and serve as a basis 
for evidence-based decision-making and policy changes in the future. 
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1 INTRODUCTION 
Human papillomavirus (HPV) was discovered in 1907, and a possible link between HPV 
infection and cervical cancer was suggested by Dr. zur Hausen in 1974 (1). HPV16 was first 
detected in a cervical cancer patient in 1983 (2). Thereafter, the causal relation between HPV 
infection and cervical cancer has been established (3, 4). Interestingly, the Papanicolaou test 
(abbreviated as Pap test, and also called “Pap smear”), was first presented by Dr. Papanikolaou 
in 1928 describing as a new diagnostic method for malignant tumors in female genital tract (5), 
which was long before the discovery of HPV as a causal agent of cervical cancer. The Pap test, 
validated as a diagnostic tool in 1943 (6), has been used in cervical screening programs for 
identifying malignancy and cell changes. The discovery of HPV and its etiological link to 
cervical cancer led to the development of HPV vaccines (7, 8). Randomized controlled trials 
of prophylactic HPV vaccines were launched in 1991 to test their protection against HPV 
infection and cervical diseases (9-11). Since 2006, the Food and Drug Administration (FDA) 
has approved three prophylactic HPV vaccines (12-14). 
Cervical screening with Pap smear has been introduced in many countries through either 
opportunistic or organized screening programs, and substantially reduced incidence and 
mortality of cervical cancer, especially in countries with an organized screening program (15) 
and for the major histological types of cervical cancer (16). HPV vaccination was introduced 
more than 10 years ago and has been shown to have tremendous population impact in reducing 
incidence of HPV infection and cervical lesions (17). Currently, a transition from cytology 
screening using Pap smears to HPV-testing as the primary screening test is ongoing, offering 
greater protection against invasive cervical cancer (18). Cervical cancer has become a 
preventable disease and we are now in an era with the potential to eliminate cervical cancer 
(19). However, some unresolved questions of scientific and strategic significance remain for 
prevention and prognosis of cervical cancer. 
This thesis investigates the association between cervical screening, HPV vaccination and risk 
of cervical cancer, the role of HPV in prognosis of cervical cancer, and how HPV vaccination 
will impact the screening strategies in practice to inform evidence-based public health policy 
change and clinical decision-making.  
 
 
 
 
 
 
 2 
2 BACKGROUND 
2.1 HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER 
More than 200 types of human papillomavirus (HPV) have been identified (20). HPV is a virus 
with double-strain deoxyribonucleic acid (DNA), and comprises 8 protein-coding genes and a 
long control region responsible for regulatory functions (21). The L1 and L2 encode capsid 
proteins, which are usually expressed at late differentiation stage of epithelium, related to virus 
assembly and released from the superficial epithelium (22). E1, E2, E4, E5, E6, and E7 encode 
proteins that contribute to replication, transcription, and transformation (21, 23). Among those, 
E6 and E7 are two major oncoproteins targeting tumor suppressor p53 and retinoblastoma 
tumor suppression protein (pRB), respectively. E6 and E7 can alter cellular proliferation, cell-
cycle progression, and apoptosis (22, 24). Additionally, they are also involved in viral DNA 
integration, malignant transformation, and the progression to cancer (22).  
HPV is the major cause for cervical cancer (25). HPV infection is the most common sexually 
transmitted infection (STI); it peaks among women at younger age (below age 25) but 
decreases afterwards (26). According to a global meta-analysis (27), the prevalence of HPV 
infection among women who had normal cytology was around 24% for women under age 25. 
A rebound of HPV infection at older ages (age≥45) in certain regions (Americas and Africa) 
has been documented (27). The International Agency for Research on Cancer (IARC) has 
classified HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 as oncogenic types and 
HPV 68 as probably oncogenic (28). Persistent infections with oncogenic HPV types cause 
most cervical cancer cases, in which HPV16 and HPV18 account for approximately 70% of all 
cervical cancer (29). In addition, anal cancer (88.0%), penile cancer (50.0%), vulvar cancer 
(24.9%), vaginal cancer (78.0%) and oropharyngeal cancer (30.8%) are attributed to HPV 
infections (30).  
Cervical cancer usually occurs in the “transformation zone” of cervix, which is an area in the 
cervix where columnar cells constantly transform into squamous cells (Figure 2.1). The entire 
anogenital epithelium can be infected by HPV, but the epithelium in transformation zone is 
especially susceptible to carcinogenesis and therefore becomes the most common area for 
abnormal cells to develop in the cervix (31). Squamous cell carcinoma and adenocarcinoma 
are two major histological types of invasive cervical cancer (25), which account for 
approximately 75% and 20% of all histological types of cervical cancer, respectively; while 
other or unspecified histological types constitute the remaining 5% (25). The 5% of uncommon 
histological types of cervical cancer are usually difficult to classify histologically, and are 
accepted as a distinct clinical-pathological entity due to their aggressive progression and worse 
prognosis compared to squamous cell carcinoma and adenocarcinoma (32, 33). 
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Figure 2.1 Anatomy of female reproductive system and transformation zone. Cancer Research UK 
copyright.  
In the natural history of cervical cancer (34) (Figure 2.2), HPV infections can usually be cleared 
without intervention within a few months, and about 90% of the infections are cleared within 
2 years (35). Only a small proportion (10%) of persistent infections with carcinogenic types of 
HPV develop into precancerous lesions (36), and if left untreated, can progress to invasive 
cervical cancer. In addition to the major risk factor – HPV infection, other non-viral factors 
(37) for cervical cancer include current smoking (37), multiparity (38), immunodeficiency, 
younger age at sexual debut (39), higher life-time number of sexual partners, poor nutritional 
status as well as long-term use of oral contraceptives (40). All non-viral factors are mainly 
associated with an elevated risk of HPV infection, persistence, and progression, and therefore 
increase the risk of cervical cancer.  
Figure 2.2 Natural history of cervical cancer. Adapted from Wright TC Jr et al (34). HPV, human 
papillomavirus. 
2.2 CERVICAL CANCER PREVENTION 
The well-established natural history of the development of cervical cancer is the basis for 
effective preventive procedures. Cervical cancer can be prevented through HPV vaccination 
(primary prevention) and cervical screening (secondary prevention). Both preventive 
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procedures aim to interrupt an intermediate step in the chain of the natural history from HPV 
infection to the occurrence of cervical cancer. 
2.2.1 Cervical screening 
Cervical screening, secondary prevention, aims to prevent the occurrence of invasive cervical 
cancer by detecting and removing precancerous lesions, which if left untreated, could develop 
into invasive cervical cancer (41). There are a variety of cervical screening methods available 
including conventional cytology, liquid-based cytology, HPV-based screening, and visual 
inspection with acetic acid or Lugol’s iodine. Usage of screening methods is usually dependent 
on the health care resources and facilities (42). Cervical screening with cytology and HPV-
based screening are commonly used in a majority of high- and middle- income countries, while 
in settings with limited resources, visual inspection with acetic acid or Lugol’s iodine could be 
alternatives. In this thesis, only cytology screening and HPV-based screening will be addressed. 
Cervical screening with cytology 
 Conventional cytology (Papanicolaou test/Pap smear): which aims to detect 
precancerous lesions before they develop into cancer through collecting cervical cell 
samples at the transformation zone and endocervical canal. The collected cervical cells 
are fixed on a glass slide and examined under the microscope for cell changes or 
abnormality. 
 Liquid-based cytology: the cervical sample is collected in the same way as a Pap smear, 
however, the sample is immersed into a conserving liquid before being fixed on the 
slide to reduce the quantity of obscuring material and therefore improve the accuracy. 
Samples taken in liquid-based cytology can provide representative residual material, 
which could be used for adjunctive testing (i.e. HPV testing).  
HPV-based screening 
HPV testing is used to detect whether a woman is infected with high-risk HPV, through 
detecting the presence of HPV DNA or messenger ribonucleic acid (mRNA) of E6 and E7 
oncoproteins in a sample of cervical cells. Samples for HPV-based screening can be 
collected by healthcare providers or by screening participants themselves with self-
sampling kits. Compared to cytology, HPV-testing offers several benefits including higher 
sensitivity in detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) lesions 
and a higher negative predictive value (NPV) (43). The disadvantage of HPV testing is its 
lower specificity in detecting CIN2+ (44).   
2.2.1.1 Cervical screening programs 
Cervical screening with cytology has been successfully implemented in many countries over 
the past decades. Given the accumulation of evidence on the advantage of HPV-based 
screening compared to cytology (18, 44, 45), a transition from cervical screening with cytology 
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to HPV-based screening as the primary screening has been ongoing in recent years. Many 
countries have issued new guidelines recommending primary HPV screening, however, the 
screening algorithms, such as age at start of screening and screening intervals, are different. In 
2015, the European guidelines (46) for cervical screening recommended HPV testing as the 
primary method in organized, population-based screening program. In the US, women aged 21 
to 29 are recommended to receive 3-year interval cytology test, and women aged 30 to 65 are 
recommended to receive 5-year interval of HPV and cytology co-test or 3-year interval 
cytology according to American Cancer Society and American Society for Colposcopy and 
Cervical Pathology (47). Since December 2017, women aged 25 - 69 years in Australia have 
been invited to HPV testing at 5-year intervals with partial HPV genotyping for HPV16/18 and 
an exit test at age 70-74 (48).  
In Sweden, cytology screening was introduced in the 1960s. Since 1998, women aged 23 - 60 
have been invited to cervical screening with cytology, with a 3-year interval for women aged 
23 - 50 and 5-year interval for women aged 51 - 60 according to national guidelines (49). In 
2015, the Swedish National Board of Health and Welfare recommended to use primary HPV 
screening for women age 30 and above because of its superiority in preventing cervical cancer 
(18, 50). However, the roll-out of primary HPV screening is not nationwide yet. As of August 
29th, 2019, 13 out of 21 regions in Sweden have implemented primary HPV screening (51). 
According to the current guidelines (50), primary screening with cytology is used for women 
age under 30 at a 3-year interval. Women aged 30 to 49 are invited to HPV screening at 3-year 
intervals and women aged 50 and above are invited to HPV screening at 7-year intervals. 
Cytological and HPV-based co-testing is recommended for women age 41. Screening will not 
stop until women have a negative screening result at least 64 years of age, and invitations 
continue until age 70 to ensure that women have a final test in the program. Cytology is used 
as the triage method for all women with HPV-positive results. Women with HPV positive but 
cytology negative results are subjected to partial HPV genotyping, and they are recommended 
for repeat HPV testing at 18 months if positive for HPV16 and/or HPV18. 
2.2.1.2 Effectiveness of cervical screening 
The burden of cervical cancer has been considerably reduced over time after the successful 
implementation of cytology screening (16, 52), especially in countries with organized cervical 
screening programs (53, 54). In countries which screening programs that suffer from low 
quality and coverage, the burden of cervical cancer has remained high (15, 16). In Nordic 
countries, cytology screening has substantially reduced the incidence (41%-49% less expected 
cases) of cervical cancer since the introduction of screening (54). Screening additionally 
contributes to early detection of cervical cancer and down-staging (32, 55), which subsequently 
improves the chances of being cured (56). In Sweden, it has been estimated that screening 
prevented almost half of the expected cervical cases between 1960s and 2000s (54). However, 
an increasing trend of cervical cancer has been observed in recent years (2014-2017), which is 
probably due to the increased exposure to HPV in younger birth cohorts and reduced sensitivity 
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of normal cytology test in some laboratories (57). The increase (around 20%) in incidence was 
mainly observed at ages under 50 and cancers diagnosed at early stage (57).  
In terms of effectiveness against different histological types, cytology screening has been found 
to be effective in preventing squamous cell carcinoma (32, 55, 58), and adenocarcinoma to 
some extent (55, 59). Evidence on other uncommon types of cervical cancer is absent, aside 
from the limited evidence on effectiveness of screening against adenosquamous cell carcinoma 
(ASC) (59, 60). Evaluating screening and risk of uncommon types of cervical cancer has been 
challenging, considering the limited number of cases, availability of cervical screening 
information, and the difficulties in classification of histological types. In existing studies, they 
were usually classified as “non-squamous cell carcinoma”, “other types” or simply excluded 
(32, 59). Over the decades, the incidence of uncommon types varied across countries (49, 53, 
61), which could be due to inconsistency in histological classification.  
2.2.2 HPV vaccination  
The current prophylactic HPV vaccines are adjuvanted non-infectious recombinant vaccines, 
which are based on virus-like particles (VLPs) produced by recombinant expression of major 
capsid antigen L1. So far, three HPV vaccines have been licensed by both the FDA and the 
European Medicines Agency (EMA) to prevent HPV-related diseases that are associated with 
vaccine types.  
The quadrivalent vaccine (GardasilTM, against HPV types 6, 11, 16 and 18) was first available 
in 2006 (13) followed by bivalent vaccine (CervarixTM, against HPV types 16 and 18) in 2007 
(12). The bivalent vaccine and quadrivalent both provide protection against HPV types 16 and 
18, which account for around 70% of all cervical cancer. The quadrivalent vaccine also protects 
against HPV types 6 and 11 that cause around 90% of genital warts (62). In 2014, a 9-valent 
vaccine which covers 9 types of HPV (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) was approved 
(14), and provided protection against five additional HPV types that are attributable for 20% 
of cervical cancer (63). All HPV vaccines can be used for both females and males. In 2014, 
World Health Organization (WHO) recommended a two-dose vaccination schedule 
considering the non-inferior protection against HPV16/18 infection compared to a three-dose 
schedule (64). Thereafter, HPV vaccines could be administered either according to a 2-dose 
schedule or a 3-dose schedule depending on age at vaccination initiation (Table 2.1). 
Table 2.1 Vaccination schedules for prophylactic HPV vaccines. Source: European Medicine 
Agency (65-67). 
HPV vaccines HPV types 2-dose, age (schedule) 3-dose, age (schedule) 
Cervarix 16, 18 
9 to 14 years 
(6 months apart) 
15 years and above 
(0, 1 and 6 months) 
Gardasil 6, 11, 16 and 18 
9 to 13 years 
(6 months apart) 
14 years and above 
(0, 2 and 6 months) 
Gardasil 9 
6, 11, 16, 18, 31, 33, 
45, 52 and 58 
9 to 14 years 
(2nd dose given 5-13 months 
after the 1st dose) 
15 years and above 
(0, 2 and 6 months) 
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2.2.2.1 HPV vaccination programs 
By 12th December 2019, 124 countries and territories have implemented HPV vaccination in 
the national immunization programs (68). In Sweden, HPV vaccines were introduced in 2006. 
Starting from May 2007, HPV vaccines were subsidized for girls aged 13-17. A free-of-charge 
school-based vaccination program for girls aged 10-12 together with a catch-up vaccination 
program for girls aged 13-18 was launched in January 2012 (69). Starting in 2015, the Swedish 
guidelines were updated according to the WHO recommendation and the school-based 
program began to use a two-dose vaccination schedule for girls 10-12 (grade 5 and 6). Since 
June 2016, those who did not vaccinate through the school-based program were offered another 
chance to be vaccinated up to age 18 following a three-dose vaccination plan. Since October 
2019, the 9-valent HPV vaccine has been used for the school-based vaccination program. 
In Sweden, the vaccination coverage of at least one dose (Figure 2.3) for subsidized HPV 
vaccination was relatively low and varied from around 35% to below 10% of the target group. 
However, the vaccination coverage increased to 55-62% for the catch-up program, while 
school-based HPV vaccination coverage reached 80-86% (70, 71). The two-dose coverage of 
HPV vaccination was almost 80% for girls born 2002 onwards by the end of 2019 (72).  
 
Figure 2.3 Coverage of at least one dose of HPV vaccine in Sweden, by 2019-12-31. Provided 
by Sparén, 2020. 
2.2.2.2 Efficacy, safety and effectiveness of HPV vaccination 
The available prophylactic HPV vaccines have been shown to be remarkably safe and effective. 
Randomized controlled trials have proven the vaccine efficacy against HPV infection and 
CIN2+ for the bivalent, quadrivalent, and 9-valent vaccines (9-11). Efficacy on cross-
protection against non-vaccine HPV type 31 has been reported for quadrivalent HPV vaccine, 
and the bivalent vaccine provides further cross-protective efficacy for HPV types 31, 33, 45 
and 51 (73). The safety profiles of HPV vaccines have been demonstrated in randomized 
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controlled trials (74-78). After implementation of HPV vaccination, observational studies also 
supported that HPV vaccination was not related to increased risk of autoimmune, neurological 
and venous thromboembolic adverse events (79, 80), multiple sclerosis or other demyelinating 
diseases (81), or adverse pregnancy outcomes (82). 
Based on real-life vaccination programs, HPV vaccination was shown to be related to reduced 
risk of genital warts (83, 84), which is the first observable HPV-related clinical outcome. 
Effectiveness against high-grade cervical lesions have also been demonstrated in Sweden (85, 
86), Scotland (87), Australia (88) and US (89) by comparing vaccinated women to 
unvaccinated women, usually with a stronger protection for girls vaccinated at an earlier age. 
Recently, a global meta-analysis on the population-level impact of HPV vaccination showed 
very promising results on the protection of HPV vaccination against HPV infections, genital 
warts and CIN2+ by comparing the post-vaccination period to the pre-vaccination period (17, 
90). A herd-immunity effect among female population with vaccine coverage over 50% was 
also recorded (90). Even though HPV vaccination has been proven to be effective against 
various HPV-related outcomes, the effectiveness against cervical cancer is very limited.    
2.2.2.3 Screening in HPV-vaccinated cohorts 
The performance of screening methods can be measured by sensitivity and specificity. In 
addition to that, the positive predictive value (PPV) and NPV are also important indicators of 
performance for a diagnostic test, and they are usually affected by the prevalence of diseases 
(91). According to the Swedish screening guidelines, women below age 30 will continue to be 
tested with cytology considering the high HPV prevalence among this age group. Since the 
HPV vaccinated women are well protected against high-grade cervical lesions of cervical 
cancer, a substantial drop in the prevalence of high-grade cervical lesions is expected when 
HPV vaccinated birth cohorts enter the screening program (92). Decreased prevalence of 
cervical lesions from the HPV vaccination program will lower the PPV assuming an unchanged 
sensitivity (91, 93, 94). The consequential increase of false-positive results might potentially 
increase the diagnostic tests, psychological stress for women (93) and impact pregnancy 
outcomes (95) if unnecessary treatment is performed.  
In Sweden, birth cohorts vaccinated through opportunistic HPV vaccination and free-of-charge 
catch-up program, with low or moderate vaccine coverage, have already entered the screening 
program. When the birth cohorts vaccinated through school-based vaccination program 
(coverage over 80%) enter the screening program in 2022, this problem will be exacerbated. A 
heavy drop in the PPV of the screening test will make cytological screening very inefficient 
(93). As a contrast, HPV testing increases protection against cervical cancer with a 60% -70% 
decrease of incidence compared to cytology for women aged 30 and above (18). It also gives a 
higher NPV compared to negative cytology test, potentially allowing extension of screening 
interval for women with HPV negative results from screening program (96). 
In Scotland, the PPV of cytology for CIN2+ was found to be lower (16%) for vaccinated 
women compared to unvaccinated women (97). Results from the Compass trial in Australian 
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(98) showed an increased detection of CIN2+ by using HPV primary screening compared to 
using cytology in HPV-vaccinated birth cohorts, and higher but not statistically different 
referral rate for colposcopy for HPV-screened compared to cytology-screened women.  
2.3 CERVICAL CANCER PROGNOSIS  
Cervical cancer accounts for substantial morbidity and mortality in women worldwide. The 
five-year relative survival of cervical cancer varies across countries, and in Europe, the five-
year relative survival for women with cervical cancer was around 62% during 2000–2007 (99). 
In Nordic countries, the five-year relative survival for cervical cancer ranged from 66% to 70% 
during 2012-2016, and was 69% for women in Sweden (100).  
2.3.1 Clinical and demographic characteristics  
The prognosis of cervical cancer has been shown to be associated with several clinical 
characteristics such as age, cancer stage, and histopathological features (99, 101). Age usually 
has a negative effect on prognosis (99). The clinical stage of cervical cancer is often determined 
by the clinical features at the time of diagnosis, and mainly depends on the size of tumor, and 
risk of spread to the pelvis. It is usually classified according to the International Federation of 
Gynecology and Obstetrics (FIGO) staging system (102). FIGO stage is a strong indicator for 
prognosis of cervical cancer (56, 101), and the probability of survival decreases as the stage 
increases. In Sweden, micro-invasive (Stage IA) represents around 20% of all cases with 
younger age of cancer diagnosis and a favorable 5-year prognosis (almost 100%). Localized 
cervical cancer (Stage IB) represents about 40% of all cases and the cure proportion is 85%–
90%. The rest 40% cases are advanced (Stages II+), and they tend to have worse 5-year survival 
(lower than 50%) (56). Grade is also associated with different clinical prognosis (101). The 
uncommon histological types of cervical cancer showed a poorer prognosis compared to the 
two major types (56, 101, 103). Other factors including education (104) and tobacco smoking 
(105) were also suggested to be linked with cervical cancer prognosis. 
2.3.2 HPV status and prognosis 
Apart from clinical and demographic factors, how HPV in the invasive cervical tumor tissue is 
associated with prognosis once cancer occur has been investigated, but findings were 
conflicting (106-112). Most of the previous studies (106-109) have shown that undetectable 
HPV in tumors was associated with poorer prognosis compared to HPV-positive cervical 
cancer. However, some studies reported no difference in prognosis in relation to tumor HPV 
status (110, 111). Recently, a study evaluating the pattern of HPV integration and prognosis 
(113) showed that the extent to which the HPV was integrated can be an indicator for prognosis. 
Moreover, specific HPV types might also influence the prognosis of cervical cancer, but the 
findings were inconclusive (106, 107, 114-116).  
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3 AIMS AND RESEARCH QUESTIONS 
This thesis addresses a range of topics associated with prevention and prognosis of cervical 
cancer. It aims to provide scientific evidence on effectiveness of the preventive procedures 
against cervical cancer including HPV vaccination and cervical screening, to support the 
evidence-based decision-making for future screening strategies in post HPV vaccination era, 
and to evaluate HPV in cervical tumors as a potential biomarker for the prognosis of invasive 
cervical cancer.  
The specific research questions for each paper are illustrated in Figure 3.1. 
 
 
Figure 3.1 Overview of the thesis and research question for each paper. HPV, human 
papillomavirus. 
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4 DATA SOURCE AND LINKAGE 
4.1 ADVANCING CERVICAL CANCER ERADICATION STRATEGIES (ACCES) 
DATABASE  
Data utilized in this project was based on the ACCES database. The ACCES database was 
established in 2006, with the aim to study cervical cancer prevention with focus on HPV 
vaccination and cervical screening. The ACCES database compiled information from Swedish 
National Cervical Screening Registry (NKCx), National Cervical Cancer Audit Database, 
Swedish population and healthcare registers managed by National Board of Health and Welfare 
(NBHW, Socialstyrelsen), Statistics Sweden (Statistika Centralbyrån, SCB), and the Public 
Health Agency of Sweden (Folkhälsomyndigheten) (Figure 4.1). Data were linked at individual 
level. Up to now, the ACCES database has been updated to year 2017, and contains information 
for 7.7 million Swedish women.  
 
Figure 4.1 Framework of Advancing Cervical Cancer Eradication Strategies (ACCES) 
database and information used in the included constituent papers. HPV, human papillomavirus. 
CIN3, cervical intraepithelial neoplasia grade 3. FIGO, International Federation of Gynecology and Obstetrics. 
LISA, Longitudinal integration database for health insurance and labour market studies. 
4.1.1 Swedish National Cervical Screening Registry (NKCx) 
NKCx is a quality register, which aims to provide evidence base for the prevention of cervical 
cancer in Sweden. It serves as a base for systematical and regular surveillance and evaluation 
on cervical screening program in reducing incidence and mortality of cervical cancer, as well 
as adverse events of preventive interventions (117). NKCx was established in year 2000, and 
has complete coverage of cervical screening in the Swedish female population since 1995. 
Laboratories of cytology and histopathology in each county perform the HPV-testing, 
cytological and histopathological examinations on samples and report to NKCx. HPV-testing 
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results are also collected from the microbiological laboratories (118). NKCx captures 
invitations to cervical screening and women’s entire screening history, including cytological, 
HPV-testing and histological diagnoses, both within organized screening program and 
opportunistic screening tests. 
4.1.2 The National Cervical Cancer Audit Database 
The National Cervical Cancer Audit Database comprised of 4254 confirmed primary invasive 
epithelial cervical cancer diagnosed during 2002-2011 and thirty year-of-birth- and sex- 
matched controls for each case. All cases were reviewed by a senior gynecologist and histo-
pathologist to retrieve the medical records and confirm diagnosis. Information on FIGO stage, 
treatment (including hysterectomy, radiation, chemotherapy and palliative care), and 
histological classification were available. Formalin-fixed paraffin-embedded (FFPE) tissue 
diagnostic blocks were collected from biobanks throughout Sweden for all confirmed cervical 
cancer cases, and 2850/4254 confirmed cases had valid HPV genotypes based on L1-region. 
Information on HPV16-E7 and HPV18-E6 were available for HPV-L1-negative cases. 
4.1.3 Swedish population and healthcare registers 
Total Population Register  
Individuals residing in Sweden on a permanent basis (planning to live in Sweden for one year 
or more) were registered in the Total Population Register (TPR) with an assigned Swedish 
personal identity number (PIN) every end of the year since 31 Dec, 1968 (119). TPR contains 
an excerpt from the Tax Agency Population Register on a daily basis, and consists of life events 
including date of birth, gender, country of birth, death, emigration, immigration to Sweden and 
migration within Sweden, etc. TPR is usually used to identify at risk population controls, study 
population for cohorts, and calculate follow-up time. 
Swedish Cancer Register  
Swedish cancer register (SCR), established in year 1958 and maintained by NBHW, is a 
mandatory reporting register covering the whole Swedish population. Since the mid-1980s, the 
six regional cancer centers have been responsible for the coding and registration of cancer if 
the notifications are sent by healthcare providers (120). After verification and correction, it is 
sent annually to the NBHW to be included in the national cancer register. SCR comprises 
information of patient data (gender, place of residence at diagnosis), medical data (site of 
tumor, histological types, and date of diagnosis), and follow-up data (date and cause of death, 
migration). Information on cancer stage has been systematically recorded since 2004. 
International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) and International 
Classification of Diseases (ICD revisions 7-10) were used for the registration of site and type 
of tumor. The WHO C24 histopathological code has been used for histological types 
classification since 1958. The underreporting of SCR is very low and without major impact for 
research and surveillance purpose. 
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The Swedish Multi-Generation register 
The Swedish Multi-Generation register (MGR) is part of registration of TPR in SCB. It 
includes population (index person) born since 1932 onwards and alive by 1961. The register 
collects information on parental records of the index person, with information available on 
mothers for 97% and on fathers for 95% of the index persons (121). 
Prescribed Drug Register 
The Prescribed Drug Register (PDR) was established in July 2005 and is maintained by the 
NBHW (122). It contains information on prescribed drug utilization and expenditures with 
complete coverage since it was established. All drug prescriptions are automatically registered 
using Anatomical Therapeutic Chemical (ATC) codes, including vaccine prescriptions which 
are relevant to this thesis. Inpatient prescriptions and over-the-counter drugs are not registered 
in PDR.  
Swedish HPV Vaccination Register  
Swedish HPV Vaccination Register (SVEVAC), initiated by Public Health Agency of Sweden 
in year 2002, was a nationwide registration of HPV vaccination between 2006 and 2015. It is 
a voluntary reporting register requiring inform consent from the individual or their parent. 
Vaccination is registered anonymously if no inform consent is available. This corresponds to a 
registration record without PIN, but information on sex, birth year and date of vaccination are 
registered. In 2012, the anonymous vaccinations in SVEVAC increased in certain counties due 
to the change from opt-out to opt-in informed consent as well as online registration platform. 
It was estimated that around 85% - 90% of completed HPV vaccinations were reported in 
SVEVAC according to the number of vaccine doses sold (123). Around 25% of the 
vaccinations are registered anonymously in SVEVAC.  
National Vaccination Register 
The Public Health Agency of Sweden is responsible for the National Vaccination Register 
(NVR) (124). Since January 2013, all healthcare professionals were obligated to report 
vaccinations administered within the childhood vaccination program to NVR. Information in 
NVR covers date of the vaccination, PIN, vaccine used, batch number and the healthcare 
provider responsible for the vaccination. HPV vaccination through the school-based program 
has been registered in NVR with identity since 2013. HPV vaccinations taken within the 
vaccination program from birth cohort 1999 onwards and up to age 21 are recorded in NVR. 
Patient register 
The patient register (PR) was established in 1964 and has achieved nationwide coverage since 
1987. The register comprises information on hospital discharge, diagnosis and surgical 
procedures. Swedish international classification system was used to register the diagnosis 
(1964-1968: ICD-7, 1969-1986: ICD-8, 1987-1996: ICD-9, and 1997 onwards: ICD-10). The 
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register contains patient information on all doctor visits in closed and specialized open health 
care. Since 2001, out-patient hospital visits from both public and private care providers have 
also been registered in the PR. The overall coverage of PR is around 80% (almost 100% for 
public hospital visits) (125). Data from primary care is not in the register. Since 2015, the 
reporting to the PR has been performed monthly instead of annually. 
Longitudinal integration database for health insurance and labour market studies  
The longitudinal integration database for health insurance and labour market studies (LISA) 
database is operated by SCB, and included individuals aged 16 and above that were registered 
in Sweden during 1990-2009, and individuals aged 15 and above since 2010 (126). The 
database integrates data from the educational sectors, social sectors and labor market, and 
updates annually with a separated new register. Information in LISA database includes 
education, individual income and family income. 
4.2 ETHICAL CONSIDERATIONS AND DATA LINKAGE 
The studies included in this thesis are largely depended on data from Swedish population and 
healthcare registries. In Sweden, the register-based research is protected by law, and all projects 
should be approved by the Ethical Review Authority (former Ethical Review Boards). 
Register-based research is commonly not deviated from clinical routine nor involved direct 
contact with the study participants, and therefore, inform consent could be waived.  
Once the ethical permit for the project is granted, data is sent to SCB and linked based on the 
Swedish PIN, which was established in 1947 and serves as a unique identifier in Swedish 
healthcare system as well as many other areas of the society (127). The PIN enable linkages 
between population registers and large-scale medical registers allowing for virtually 100% 
complete coverage in Swedish healthcare system. The SCB replaces the PIN by a 
corresponding sequential number before data is delivered for research purposes. Data usage is 
under strict regulation, and delivered data can not be used for purposes other than approval 
from the Ethical Review Authority. Re-use of data is possible if the analysis is within the field 
covered by approval, or an amendment of ethical approval for that specific research purpose is 
granted.   
All studies included in this thesis were approved by the Regional Ethical Review Board in 
Stockholm. Informed consent from the study participants was waived due to the population-
based nature of the study. Ethical approvals related to this thesis work include: Dnr 2011/1026-
31/4; Dnr 2012/1028/32; Dnr 02-556; Dnr 2011/921-32; Dnr 2012/216-32; Dnr 2012/1426-32 
and Dnr 2014/246-32.  
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5 METHODS 
An overview of study design, study population, main measurements and statistical methods for 
each paper included in the thesis is presented in Figure 5.1. 
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5.1 STUDY DESIGN AND STUDY POPULATION 
5.1.1 Nested case-control design 
The nested case-control design, which is an extension of the general case-control design, has 
been widely used in epidemiological research. In a nested case-control study, cases occurring 
within the defined cohort are identified, and a specific number of controls are selected among 
population who have not yet developed the defined disease at the time of occurrence of an 
index case (128). The selection of cases and controls are incidence density sampling, also called 
“risk-set sampling” (Figure 5.2), which allows for matching on time. Matching on other factors 
(e.g. age and sex) can also be applied in such a design to rule out a potential confounding effect. 
A nested case-control design was used in paper I. 
 
Figure 5.2 Illustration of incidence density sampling in nested case-control design. The sampling 
ratio of cases to controls here is 1:2. 
5.1.1.1 Paper I 
We aimed to examine the association between cervical cytology screening and risk of ASC and 
rare histological types of invasive cervical carcinoma (RICC). Cases and controls were 
identified from a cohort of Swedish women born between 1909-1986 with a follow-up during 
2002-2011. We included women diagnosed as ASC and RICC (n=338) and thirty year-of-birth-
matched controls for each case, randomly selected from TPR utilizing incidence density 
sampling. All controls were alive, with no history of cervical cancer and living in Sweden 
before the cancer diagnosis of their corresponding case. Among those, 449 controls who had 
total hysterectomy were excluded, because they were not at risk of cervical cancer from that 
point in time. In total, we included 9691 matched controls. 
5.1.2 Population-based cohort design 
Cohort studies track time from exposure to outcome between at least two groups of individuals 
either prospectively or retrospectively, and are usually helpful in investigating the incidence or 
natural history of diseases (129). Cohort studies require clear and objective definitions of both 
exposure and outcome, and are commonly used for examining multiple outcomes after a single 
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exposure. In such a design, all participants included (both exposed and unexposed groups) 
should be at risk of developing the diseases of interest, and importantly the unexposed group 
should resemble the exposed group in all aspects except for the absence of exposure. The 
population-based cohort design was used for papers II, III & IV. 
5.1.2.1 Paper II 
We aimed to evaluate the association between tumor HPV status and invasive cervical cancer 
prognosis. We included invasive cervical cancer cases diagnosed in Sweden during 2002-2011 
(confirmed as primary invasive epithelial cervical cancer), and with valid HPV results based 
on the archived diagnostic blocks (Figure 5.3). A total of 2845 cases were included and 
prospectively followed up from date of cancer diagnosis to 31 December, 2015, migration from 
Sweden, or death, whichever occurred first.  
 
Figure 5.3 Study population for paper II. HPV, human papillomavirus; FFPE, formalin-fixed paraffin-
embedded. 
5.1.2.2 Paper III 
The aim was to examine how HPV vaccination would affect the PPV of cytology. We identified 
women born between 1989 and 1993, who were resident in Sweden since the introduction of 
HPV vaccination (October, 2006) and eligible for screening. Among those, we included 
women who attended cervical screening at age 23 and had valid histopathological diagnosis 
based on records from NKCx (Figure 5.4).  
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Figure 5.4 Study population for paper III. HPV, human papillomavirus. 
5.1.2.3 Paper IV 
To investigate the association between HPV vaccination and risk of invasive cervical cancer, 
we included a cohort of women age 15 to 30 during 2006-2017 (Figure 5.5). The entry of the 
study was defined as either age 15 or 1 Jan, 2006 whichever came last. We excluded women 
who immigrated to Sweden after 1 Jan, 2006, died, emigrated or were lost to follow-up before 
entry of the study, and women with a diagnosis of invasive cervical cancer before entry to the 
cohort. We followed all eligible participants prospectively to a diagnosis of invasive cervical 
cancer, death, emigration, 31st birthday or 31 December, 2017 whichever came first.  
 
Figure 5.5 Study population for paper IV.  
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5.2 MAIN MEASUREMENTS 
5.2.1 Invasive cervical cancer (papers I, II & IV) 
Invasive cervical cancer in papers I and II were based on the National Cervical Cancer Audit 
Database (derived from SCR), where all cases were confirmed as primary, invasive, epithelial 
cancer with cervix origin after review of medical records and histopathological review. The 
histological types were classified as squamous cell carcinoma, adenocarcinoma, ASC and 
RICC (including glassy cell carcinoma, clear cell carcinoma, small cell carcinoma, 
neuroendocrine carcinoma, large cell carcinoma, and undifferentiated carcinoma). Cancer 
stage was classified based on the FIGO staging system, and categorized as stage IA 
(microinvasive), IB (localized), and II+ (advanced cancer) (102). In paper IV, the invasive 
cervical cancers were retrieved from SCR using ICD-10 (code: C53). 
5.2.2 Cervical screening (papers I & III) 
Cervical screening was obtained from NKCx. In paper I, cervical screening was measured 
during the last two recommended screening intervals 6 months prior to diagnosis of cervical 
cancer, with regard to age at cancer diagnosis (Figure 5.6). We measured the cervical screening 
as screening status and screening history. Screening status was classified as “no test”, “one 
test”, and “two tests”. Screening history was categorized as “no test”, “double normal results”, 
“one normal result only” and “at least one abnormal result” based on the cytological results. 
The cytological and histopathological diagnoses were based on the Systematized Nomenclature 
of Medicine (SNOMED) codes defined by the Swedish Association of Clinical Cytology and 
Swedish Society of Pathology, respectively (Table 5.1).  
In paper III, cervical screening was measured as both cytological results and histopathological 
diagnoses. Women’s first cytology at age 23 were classified as normal cytology, low-grade 
cytology and high-grade cytology (Table 5.1). If an abnormal cytological result was present, 
we further linked to histopathological diagnosis and identified women confirmed as CIN2+ 
within 6 months after high-grade cytology, and within 12 months after low-grade cytology.  
 
Figure 5.6 Evaluated screening intervals depending on age at cancer diagnosis. Screening tests 
taken within 6 months prior to diagnosis of cervical cancer was disregarded as they were diagnostic tests and not 
preventing cervical cancer. 
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Table 5.1 Systematized Nomenclature of Medicine (SNOMED) codes for cytological and 
histopathological diagnoses. 
Outcome SNOMED code 
Normal cytological diagnoses 
 Benign sample M00110 
Abnormal cytological diagnoses 
Low-grade cytology  
 Atypical squamous cell of undetermined significance (ASCUS) M69710 
 Mild dysplasia/Cervical intraepithelial neoplasia (CIN) 1 M74006 
High-grade cytology  
 Atypia in cells of uncertain origin M69700 
 Atypical glandular cells (AGC) M69720 
 Moderate dysplasia/Cervical intraepithelial neoplasia (CIN) 2 M74007 
 Severe dysplasia/Cervical intraepithelial neoplasia (CIN) 3/Cancer in situ (CIS) M80702 
 Suspected high-grade dysplasia (ASC-H) M69719 
 Squamous cell carcinoma M80703 
 Adenocarcinoma/Adenocarcinoma in situ (AIS) M81403 
Histopathological diagnoses of CIN2+  
 Cervical intraepithelial neoplasia grade 2 M74007 
 Cervical intraepithelial neoplasia grade 3 M80702 
 Carcinoma in situ M80762 
 Adenocarcinoma in situ M81402 
 Adenosquamous cell cancer in situ M85602 
 Invasive cervical cancer of any origin  
M80703, M81401, 
M81403, M85601, 
M85603, M80413 
5.2.3 HPV genotypes (paper II) 
HPV genotypes were derived from the National Cervical Cancer Audit Database. FFPE 
diagnostic samples for all confirmed invasive cervical cancer cases during 2002-2011 were 
collected from biobanks in Sweden. The available FFPE blocks were extracted and tested in 
parallel with β-globin real-time polymerase chain reaction (PCR). We performed the HPV 
typing using general primers (MGP)-PCR targeting the L1 region (130), followed by typing 
with Luminex for 13 high risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and non-
high risk types (6, 11, 26, 30, 40, 42, 43, 53, 54, 61, 66, 67, 69, 70, 73, 74, 81, 82, 83, 86, 87, 
89, 90, 91) (28, 131). Real-time PCR test for HPV16-E7 and HPV18-E6 was performed for 
samples turned out to be HPV-negative based on L1 region (132). This was because the L1 
region might lost during the carcinogenesis, while the oncogenic E6 and E7 regions were more 
likely to be retained (133). To investigate the distribution of HPV genotypes in tumor tissues 
for ASC and RICC in paper I, the tumor HPV genotypes were categorized as HPV 16, HPV18, 
other high-risk human papillomavirus (hrHPV)-positive and hrHPV-negative. In paper II, 
tumor HPV status was the exposure, and classified as hrHPV-positive and hrHPV-negative 
based on the L1 region.  
5.2.4 HPV vaccination (papers III & IV) 
Records of HPV vaccination in paper III and IV were retrieved from three different registers 
including PDR, SVEVAC, and NVR. As SVEVAC had issues with anonymized registration 
of vaccination, the vaccination records were further complemented with dispensation dates of 
HPV vaccines from PDR based on ATC codes. The procedure was done following an algorithm 
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that HPV vaccine dispensed at least 14 days prior to the vaccination administration date were 
considered as a new dose. In both papers, vaccinated women were defined as vaccinated with 
at least one dose of HPV vaccination. Otherwise, women were classified as unvaccinated. HPV 
vaccination was also measured as age at vaccination initiation, and the cut-off of age at 
vaccination initiation was based on the previous studies on effectiveness of HPV vaccination 
(84-86).  
When we studied the effectiveness of HPV vaccination in paper IV, HPV vaccination was 
treated in a time-varying manner based on the first dose of HPV vaccination (Figure 5.7). 
Namely, if the vaccination occurred before study entry, the individual contributed person-time 
to the vaccinated group since entry to the study. If the vaccination occurred during the follow-
up, the individual started to contribute person-time to the unvaccinated group, and switched to 
the vaccinated group from the date of vaccination; otherwise they remained in the unvaccinated 
group throughout the study period. 
 
Figure 5.7 Illustration of time-varying exposure of HPV vaccination in paper IV. HPV, human 
papillomavirus. 
5.2.5 Covariates 
Several covariates were retrieved from national healthcare registers and used as exclusion 
criteria for study population or adjusted as potential confounders. In the control selection of 
paper I, we excluded controls who had a total hysterectomy before the index date based on 
information from PR, because they were no longer at risk of having invasive cervical cancer 
after such a procedure. We also measured socioeconomic status as education and income, 
which we retrieved from LISA. The educational level was classified as low (less than high 
school), middle (high school), high (university and above) and missing, and controlled in 
statistical analysis in paper I, II & IV. Income level was used in paper IV, and categorized as 
low, middle, high and missing based on tertiles of income level among the population aged 35- 
65 during years 2006-2016. Missing values of both educational level and income level were 
treated as separated subgroups, and included in the regression models. Besides, disease history 
of study participants’ mother on previous diagnosis of cervical intraepithelial neoplasia grade 
3 or worse (CIN3+) or any types of cancer were obtained from SCR, and controlled for as 
confounders in paper IV.  
 24 
5.3 STATISTICAL METHODS 
5.3.1 Conditional logistic regression 
Logistic regression investigates the association between a dichotomous dependent variable and 
explanatory variables using a logit model. Conditional logistic regression is a specialized type 
of logistic regression that also accounts for matching and stratification. The likelihood of the 
conditional logistic regression model is formulated so that cases and controls are only 
compared within the same riskset, by assuming constant odds ratios (ORs) across matched 
strata, and controlling for the matched factors through conditioning.  
In paper I, we estimated the ORs of ASC and RICC in relation to screening status and screening 
history, together with 95% confidence intervals (CIs), based on conditional logistic regression, 
further adjusted for the highest educational level achieved by the year of cancer diagnosis. 
These ORs were interpreted as incidence rate ratios (IRRs) (134, 135). 
5.3.2 Relative survival 
Relative survival is calculated as the all-cause survival of a cancer population, divided by the 
expected all-cause survival of that population if they were cancer-free. Relative survival can 
be used as an estimate for net survival, which measures the survival probability after a cancer 
diagnosis while removing deaths due to other causes. Crucially, net survival does not depend 
on the availability of reliable cause of death information. The corresponding concept to relative 
survival on the hazard scale  is named excess mortality, defined as the difference between the 
all-cause mortality observed in the cohort of cancer population and the expected mortality if 
the population were cancer-free (136). Relative survival relies on two general assumptions: 
firstly, that the expected mortality in the cancer population and the general population are 
independent, conditional on the matching variables (e.g. age, sex, calendar year) and covariates 
included in the model; secondly, that the expected mortality in the general population is 
exchangeable with the mortality in the cancer population if they were cancer-free. 
In paper II, we estimated net survival within the relative survival framework, assuming that 
cervical cancer cases were comparable to the general female population of the same age during 
the same calendar period if they did not have cancer. The life table method (136) was used to 
estimate five-year relative survival ratios (RSRs) in relation to tumor hrHPV status.   
5.3.3 Poisson regression  
The Poisson regression model is a type of generalized linear model, which is commonly used 
for count data, but can also be applied to time-to-event data (137). In survival analysis, a 
Poisson regression models the incidence rates (IRs), and provides estimates for the log-IRRs 
relative to the baseline IR for each comparison group via their regression coefficients. The 
shape of the baseline IR can be chosen to fit the data,  from a simple constant rate across the 
follow-up time, piece-wise constant rate over shorter intervals of follow-up time (i.e. a step 
function), or as a restricted cubic spline smooth over the same shorter time intervals. The 
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Poisson model is a parametric model, generally assuming proportional hazards, though it can 
model non-proportional effects via interactions with the time scale.  
In paper II, we used a Poisson regression model to estimate both crude and adjusted excess 
hazard ratios (EHRs) with 95% CIs, assuming piece-wise constant hazards in in 1-year time 
bands after diagnosis; we also adjusted the model for age at diagnosis, FIGO stage, time after 
cancer diagnosis, and educational level. In paper IV, we used Poisson regression to model the 
IR of cervical cancer over attained age in 1-year time bands up to age 30 using a spline term, 
and estimated the IRRs (with 95% CIs) between vaccinated and unvaccinated women, 
controlling for county of residence and parental characteristics. 
5.3.4 Log-binominal regression  
Log-binominal regression is a generalized linear model in the binomial family, with a log link 
function, and commonly used as an alternative to the logistic regression model for cohort data 
where the outcome is not rare. The coefficients from log-binomial regression model can be 
interpreted as estimated risk ratios (RRs). In paper III, the PPV is calculated as the number of 
women screen-positive and confirmed as CIN2+ in histopathological diagnosis, divided by the 
number of women screen-positive. To investigate changes in PPV, we modelled the crude and 
birth-cohort-adjusted RRs of PPV for CIN2+ with 95% CI in relation to age of HPV 
vaccination initiation, using log-binominal regression. The change of PPV was presented as (1-
RR)*100%. 
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6 MAIN FINDINGS 
6.1 CERVICAL SCREENING AND RISK OF ADENOSQUAMOUS CELL 
CARCINOMA AND RARE INVASIVE CERVICAL CARCINOMA. 
We included a total of 338 cases, which consist of 164 (49%) cases of ASC and 174 (51%) 
cases of RICC. The RICC consists of 43 cases of glassy cell carcinoma, 31 cases of clear cell 
carcinoma, and 100 cases of other rare types of invasive cervical carcinoma.  
A reduced risk of ASC (IRR 0.22, 95% CI 0.14 - 0.34) and RICC (0.34, 95% CI 0.21 - 0.55) 
was observed for women who had screening tests in both of the previous two recommended 
screening intervals compared to women without any screening tests (Figure 6.1). The risk 
reduction for women who only had a screening test in one of the recommended screening 
intervals was attenuated compared to women had screening tests in both intervals (ASC: 0.39, 
95% CI 0.26 - 0.59; RICC: 0.69, 95% CI 0.45 - 1.06).  
 
Figure 6.1 Incidence rate ratio (IRR) of adenosquamous cell carcinoma (ASC) and rare types 
of invasive cervical carcinoma (RICC) by screening status in the two previous screening 
intervals in women aged over 30. Reference group: no test. RICC includes glassy cell carcinoma, clear cell 
carcinoma, and other rare types. IRR is adjusted for educational level and age. Figures were based on estimates 
from table 2 in paper I.  
With regard to the screening history, women having two normal tests were associated with a 
significantly lower risk of ASC (0.16, 95% CI 0.10 - 0.26) and RICC (0.29, 95% CI 0.17 - 
0.48), respectively. However, having at least one abnormal test was related to an elevated but 
not statistically significant risk of both ASC and RICC compared to women did not have any 
tests (Figure 6.2). 
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Figure 6.2 Incidence rate ratio (IRR) of adenosquamous cell carcinoma (ASC) and rare types 
of invasive cervical carcinoma (RICC) by screening history in the two previous screening 
intervals in women aged over 30. Reference group: no test. RICC includes glassy cell carcinoma, clear cell 
carcinoma, and other rare types. IRR is adjusted for educational level and age. Figures were based on estimates 
from table 3 in paper I. 
Examining the tumor HPV genotypes distribution among 211 cases of ASC and RICC with 
valid HPV results, we found 148 (70%) cases were hrHPV-positive. HPV18 (37%) was the 
most common HPV type detected in tumor tissues, and HPV16 and other hrHPV types was 
detected in 22% and 10% of the cases, respectively (Table 6.1). 
Table 6.1 Tumor human papillomavirus (HPV) status of adenosquamous cell carcinoma and 
rare types of invasive cervical carcinoma. Values are number (percentages). Table 5 in paper I. 
 
6.2 TUMOR HIGH-RISK HPV STATUS AND PROGNOSIS OF INVASIVE 
CERVICAL CANCER. 
We included 2845 cases, and the L1 region of hrHPV was found in tumors among 2293 
(83.1%) cases. During the follow-up (an average of 6.2 years), we observed 822 deaths (36.3%) 
in hrHPV L1-positive cases and 309 deaths (56.0%) in hrHPV L1-negative cases.  
The hrHPV-positive cases had a constantly better cumulative relative survival than hrHPV-
negative cases during the follow-up period (Figure 6.3). The five-year RSR was 0.74 (95% CI, 
0.72 - 0.76) for hrHPV-positive cases, 0.54 (95% CI, 0.50 - 0.59) for hrHPV-negative cases. 
Compared to hrHPV-negative cases, the crude EHR was 0.45 (95% CI 0.38 - 0.52) and the 
adjusted-EHR was 0.61 (95% CI 0.52 - 0.71) for hrHPV-positive cases. This indicated a 39% 
significantly lower excess mortality for cases with hrHPV-positive tumors compared to cases 
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with hrHPV-negative tumors, after controlling for age at diagnosis, FIGO stage, time after 
cancer diagnosis in 1-year time bands, and educational level.  
 
Figure 6.3 Cumulative relative survival of invasive cervical cancer cases by tumor high-risk 
human papillomavirus (hrHPV) status. hrHPV, high-risk human papillomavirus. Fig. 2 in paper II. 
Stratified by age at cancer diagnosis, the five-year adjusted EHRs for hrHPV-positive cases 
were between 0.55 and 0.66 across age groups compared to hrHPV-negative cases (Figure 6.4). 
After stratifying by FIGO stage, the adjusted EHRs of hrHPV-positive cases were between 
0.59 and 0.62 for cases diagnosed at stages above IA compared to hrHPV-negative cases.  
 
Figure 6.4 Excess hazard mortality of invasive cervical cancer cases in relation to tumor high-
risk human papillomavirus (hrHPV) status by age at cancer diagnosis (left) and FIGO stage 
(right). *Upper bound of confidence intervals for cases diagnosed at stage IA were truncated for display purpose. 
FIGO, International Federation of Gynecology and Obstetrics. Adapted from fig. 3 in paper II. 
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6.3 SCREENING PERFORMANCE OF CYTOLOGY TEST AMONG HPV-
VACCINATED COHORTS. 
A total of 153,250 women born during 1989-1993 who attended cervical screening at age 23 
were included. Among those, 2,729 (1.8%) women had high-grade cytology, 18,094 (11.8%) 
women had low-grade cytology, and the rest of 132,427 (86.4%) women had normal cytology. 
For women with high-grade cytology, the detection rate of CIN2+ was 1.5% (95% CI, 1.4% -
1.5%), 0.9% (95% CI, 0.8% - 1.0%), and 0.5% (95% CI, 0.5% - 0.6%) for women 
unvaccinated, initiating vaccination at age 17-22, and initiating vaccination before age 17 
(Figure 6.5, Panel A). Correspondingly, the PPV of high-grade cytology for CIN2+ was 69.9% 
(95% CI, 67.9% - 71.9%), 64.9% (95% CI, 59.8% - 69.8%) and 57.4% (95% CI, 50.9% - 
63.7%) (Figure 6.5, Panel C). This corresponded to a PPV reduction of 8% (RR 0.92, 95% CI 
0.85 - 1.00) and 17% (RR 0.83, 95% CI 0.74 - 0.93) respectively among women initiating 
vaccination at age 17-22 and women initiating vaccination before age 17 compared to 
unvaccinated women, after adjustment for birth cohort.  
 
Figure 6.5 Detection rate (Panel A&B) and positive predictive values (Panel C&D) by age at 
HPV vaccination. CIN2+, cervical intraepithelial neoplasia grade 2 or worse. PPV, positive predictive value. 
Values are percentage. Figures were based on estimates from table 1 in paper III.  
Complementary, the detection rate of CIN2+ after having low-grade cytology was 2.3% (95% 
CI, 2.2% - 2.4%) for unvaccinated women, 1.4% (95% CI, 1.3% - 1.5%) for women initiated 
vaccination at age 17-22 and 1.0% (95% CI, 0.9% - 1.0%) of women initiating vaccination 
before age 17 (Figure 6.5, Panel B). The corresponding PPVs for CIN2+ were 18.9% (95% CI, 
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18.2% - 19.6%), 12.8% (95% CI, 11.6% - 14.1%), and 9.3% (95% CI, 8.2% - 10.4%), 
respectively (Figure 6.5, Panel D). Compared to unvaccinated women, the PPV declined for 
women initiating vaccination at age 17-22 (RR 0.72, 95% CI 0.65 - 0.80) and initiation 
vaccination before age 17 (RR 0.56, 95% CI 0.49 - 0.63) after adjustment for birth cohort. 
6.4 HPV VACCINATION AND RISK OF INVASIVE CERVICAL CANCER. 
A cohort of 1,427,619 women aged 15-30 during 2006-2017 were included, and 383,694 
(26.9%) of them were vaccinated with at least one dose of HPV vaccination. The number of 
women completed three doses of vaccination were 296,595, representing 77.3% of vaccinated 
women. Looking at the age at vaccination initiation, 293,977 (76.6%) of the vaccinated women 
initiated vaccination before age 17, and 89,717 (23.4%) initiated vaccination at age 17 and 
above.  
During the follow-up period, we observed 19 cases of invasive cervical cancer among 
vaccinated women (mean follow-up: 5y) and 538 cervical cancer cases among unvaccinated 
women (mean follow-up: 6.6y). The cumulative incidence proportion before age 20 was 
extremely low, but showed a sudden increase of cervical cancer for both vaccinated and 
unvaccinated women at age 23 (Figure 6.6). Onwards, the increase of cumulative incidence 
proportion among unvaccinated women was greater compared to vaccinated women, and it 
was constantly higher in unvaccinated than vaccinated women by age 31.  
 
Figure 6.6 Cumulative incidence proportion of invasive cervical cancer by HPV vaccination 
status. HPV, human papillomavirus. Fig. 2 in paper IV. 
The crude IR of invasive cervical cancer for unvaccinated women was 6.65 (95% CI, 6.12 - 
7.24) while it was 1.00 (95% CI, 0.64 - 1.56) for vaccinated women. This led to an age-adjusted 
IRR of 0.50 (95% CI, 0.32 - 0.80) for vaccinated women compared to unvaccinated women 
(Table 6.2). Using Poisson regression model, we also adjusted for other covariates including 
county of residence and parental characteristics. The results showed the incidence among 
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vaccinated women was 52% (IRR 0.48, 95% CI 0.30 - 0.76) lower compared to unvaccinated 
women. Stratifying by age at vaccination initiation, we observed a more pronounced risk 
reduction among women initiating vaccination before age 17 with a reduction of 83% (IRR 
0.17, 95% CI 0.04 - 0.69), while for women initiating at age 17-30 we observed a risk reduction 
of 40%  (IRR 0.60, 95% CI 0.37 - 0.97). 
Table 6.2 Age at HPV vaccination initiation and incidence rate ratios (IRRs) of invasive 
cervical cancer. Table 2 in paper IV. 
HPV 
vaccination 
No. of 
cases 
Person-time 
(years) 
Crude incidence 
rate (95% CI)a 
Age-adjusted 
IRR 
(95% CI) 
Adjusted-IRR 
(95% CI)b 
Unvaccinated 538 8,084,415 6.65 (6.12 - 7.24) Ref. Ref. 
Vaccinated 19 1,906,704 1.00 (0.64 - 1.56) 0.50 (0.32 - 0.80) 0.48 (0.30 - 0.76) 
      
Vaccinated      
age<17 2 1,338,440 0.15 (0.04 - 0.60) 0.18 (0.04 - 0.73) 0.17 (0.04 - 0.69) 
age 17-30 17 568,263 2.99 (1.86 - 4.81) 0.63 (0.39 - 1.02) 0.60 (0.37 - 0.97) 
      
Vaccinated      
age<20 12 1,768,836 0.68 (0.39 - 1.19) 0.51 (0.28 - 0.91) 0.48 (0.26 - 0.86) 
age 20-30 7 137,868 5.08 (2.42 - 10.65) 0.50 (0.24 - 1.05) 0.48 (0.22 - 1.01) 
a. Per 100,000 person-years 
b. Adjusted for age as a spline term with 3 degree of freedom, county of residence, mother's country of 
birth, highest parental educational level, highest annual family income level, mother’s cervical 
intraepithelial neoplasia grade 3 or worse (CIN3+) history, and mother’s previous diagnosis of cancers 
other than cervical cancer. 
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7 DISCUSSION 
7.1 METHODOLOGICAL CONSIDERATIONS 
7.1.1 Study design 
The case-control study design is considered to be time and resource saving, but compromises 
with loss of efficiency compared to a full-cohort design. In paper I, we used the nested case-
control study design, and selected controls using incidence density sampling within a dynamic 
cohort, meaning the controls were selected in proportion to their contribution to the person-
time at risk (138). Therefore, the ORs in our study can be interpreted as IRRs (135). 
Additionally, we have previous evaluated the screening and risk of the two major types of 
cervical cancer (32, 55) in a nested case-control study. Using the same study design allows us 
to compare the effect size of screening and risk of different histological types of cervical cancer 
to some extent, which is of great interest when the knowledge on screening and risk of ASC 
and RICC is limited. In papers II, III & IV, a population-based cohort design was used as we 
were interested both in absolute and relative risk between the comparison groups. Cohort 
studies are usually very costly, time-consuming on data collection and informative censoring 
can introduce bias. However, given the unique opportunities of rich healthcare registers with 
routinely collected high-quality data, and the individual linkage possibilities with PIN in 
Sweden, a population-based cohort design based on virtually complete data excludes recall bias 
and largely minimize selection bias, misclassification and loss to follow-up.  
7.1.2 Confounding 
Confounding refers to a situation where the effect of the exposure on the outcome is a mixed 
with effects of other variables. Confounders are defined as factors related to both exposure and 
disease, but not an intermediate step in the causal pathway between them (138).  Confounding 
can be controlled at the stage of study design (randomization, restriction, and matching) or 
during data analysis (regression adjustment and stratification). 
7.1.2.1 Age and birth cohort 
Age is a major confounder for all research questions in this thesis. The incidence of HPV-
related diseases and all-cause mortality are strongly related to age. Birth cohort is strongly 
associated with HPV vaccination uptake, and somewhat related to incidence of HPV-related 
diseases. Under a specified observational period, age and birth cohort are exchangeable.  
We matched on year of birth when selecting controls in paper I to reduce confounding. Since 
we used incidence density sampling, matching on year of birth was equivalent to matching by 
age. All matching factors, including year of birth, were implicitly adjusted for in the conditional 
logistic regression model. In paper II, age at cancer diagnosis could be both a confounder and 
effect modifier for association between hrHPV status and prognosis of cervical cancer. We 
included age as a spline term in the regression model, and additionally stratified the analysis 
by age groups, with adjustment for age within each stratum, to examine whether the association 
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varied. When investigating the PPV of cytology in paper III, we adjusted for birth cohort, since 
we only examined cytology screening tests at age 23. In paper IV, we used attained age as the 
underlying time-scale, and adjusted for it via a spline term in the analysis. Birth cohort was 
considered as an interaction term with HPV vaccination status, and we also computed the IRRs 
for vaccinated compared to unvaccinated women in separate birth cohort strata. 
7.1.2.2 Behavioral factors 
A major challenge in register-based studies is the absence of information on covariates such as 
lifestyle factors, smoking, number of sexual partners, and STIs, as these behavioral factors are 
not easily available from health-care registers. We attempted to minimize the confounding 
effects through adjustment for proxy factors available from nationwide registers. Controlling 
for such factors is essential, because they are usually related to health seeking behavior, which 
corresponds to screening attendance and vaccine uptake in this thesis. Meanwhile, these factors 
could also influence the risk of cervical diseases and death. Therefore, we retrieved information 
on educational level (paper I, II & IV) and income level (paper IV) to serve as proxies of 
lifestyle factors, smoking and STIs, and included them in the regression models to minimize 
confounding. However, we were to acknowledge that any observational study, even if it is in 
possession of a rich set of covariates, may be afflicted by residual confounding. 
7.1.3 Selection bias 
Selection bias is a systematic error derived from selecting subjects from factors that affect study 
participation. In all papers, we used the entire Swedish population, and therefore, the selection 
bias that comes from an unrepresentative study population should be limited. However, the 
selection bias can exist in other forms. 
7.1.3.1 Healthy volunteer bias  
We examined the impact of preventive strategies including cervical screening and HPV 
vaccination on the risk of cervical cancer. Individuals attending screening and vaccinating 
could be generally more health-conscious, leading to so called “healthy volunteer bias”. If so, 
we would more likely to overestimate the protective effect of screening or HPV vaccination, 
which applies to paper I and paper IV. We therefore controlled for education in the regression 
model as a proxy for the health consciousness in order to minimize such a bias in paper I. 
Furthermore, we assessed the potential healthy volunteer bias by conducting an identical nested 
case-control analysis examining screening and risk of stomach cancer and rectal cancer as two 
separate outcomes, which do not benefit from cervical screening. The results showed women 
participating in cervical screening in the last screening interval had an IRR of 0.91 (95% CI: 
0.84 - 0.99) for stomach cancer, compared to women not participating, while the corresponding 
IRR for rectal cancer was 0.87 (95% CI: 0.82 - 0.91). We concluded that a healthy volunteer 
effect in terms of screening could account for a general risk reduction of cancer of around 10%, 
but likely not more than 15%. In paper IV, study participants were mainly vaccinated through 
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opportunistic or free-of-charge catch-up vaccination program, and healthy volunteer bias could 
play a role here. In the regression model, we controlled for residential factors and parental 
characteristics in terms of education, income, country of birth, and previous disease history, 
and the estimates remained essentially unchanged.  
7.1.3.2 Detection bias 
Vaccinated individuals were more likely to attend screening (139, 140), which is linked to 
higher chances for detecting asymptomatic cervical disease as compared to women who did 
not vaccinated. This could lead to an underestimation of the effectiveness of HPV vaccination 
in paper IV, because the vaccinated women were more likely to detect otherwise asymptomatic 
cervical cancer in screening. However, attending screening can also prevent cervical cancer 
through detection and treatment of precancerous lesions. If vaccinated women had higher 
screening attendance than unvaccinated women, more cancers might have been prevented 
through screening in the vaccinated group, which would result in an overestimation of the 
effectiveness of HPV vaccination. In this case, as cancers occurring before age 31 typically 
follow more aggressive clinical course, the likelihood of prevention through screening should 
be limited.  
7.1.3.3 Lead time and length bias 
Lead time bias and length bias should be noted when evaluating the benefits of screening on 
survival. Lead time bias means that the screened population could show a falsely improved 
cancer survival because the cancer is diagnosed earlier through screening before showing 
symptoms. Length bias refers to the fact that aggressive tumors having a shorter preclinical 
period than non-aggressive tumors, and screening would be likely to detect non-aggressive 
tumors than aggressive tumors, leading to a biased estimation of cancer survival. 
In paper II, we did not study the benefits of screening on cancer survival directly, but women 
with hrHPV-positive tumors were more likely to be screen-detected compared to women with 
hrHPV-negative tumors. If there were differences in the clinical course with regard to tumor 
HPV status, we suspected hrHPV-positive tumors to be less aggressive and with a longer 
preclinical time-window to be detected in screening. To minimize this bias, we controlled for 
cancer stage in the main analysis, which to some extent accounts for these aspects. In addition, 
we stratified the comparison by mode of cancer detection, and found the difference of prognosis 
with regard to tumor hrHPV status remained. 
7.1.4 Misclassification 
7.1.4.1 HPV vaccination 
The major source of misclassification in this thesis is misclassification of HPV vaccination 
status, due to the anonymous registration of vaccination records in SVEVAC. In the 
opportunistic vaccination period (2006-2011), individuals could receive the reimbursement 
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only if the vaccines were prescribed, so that the vaccination would be registered in the PDR. 
We used this information to complement vaccination records in both papers II & IV, which 
should minimize the misclassification of HPV vaccination during that period. However, a small 
proportion of school-based vaccinations and catch-up vaccinations could not be complemented 
with information from the PDR in this manner. This mainly applied to vaccinations through 
school-based programs in 2012, and catch-up vaccinations from 2012 onwards. Misclassifying 
vaccinated women as unvaccinated will result in an underestimation of PPV changes for 
vaccinated compared to unvaccinated women (paper III) and underestimation of the 
effectiveness of HPV vaccination (paper IV). 
7.1.4.2 Invasive cervical cancer 
We carefully reviewed medical charts with additional histopathological reviews to ensure the 
diagnosis of all cervical cancer in the National Cervical Cancer Audit Database. Cases which 
were not primary, invasive, epithelial (e.g. sarcoma, endometrial cancer), or reoccurrent cases 
were excluded. Therefore, misclassification of invasive cervical cancer in this scenario was 
highly unlikely. However, to include those cases would introduce misclassification. This could 
potentially dilute the association between screening and risk of ASC and RICC, and bias the 
distribution of HPV types in paper I. Meanwhile, this would also increase the case load of 
hrHPV-negative tumors, meaning our estimates could be biased in either directions in paper II.  
7.1.4.3 Tumor HPV status 
Besides from mistakenly classifying non-cervical cancer as cervical cancer, another argument 
against HPV-negative cervical cancers was the laboratory tests were simply not sensitive 
enough to detect HPV types in some tumors, which would lead to misclassification. This could 
be due to poor quality of samples or inefficient amplification of the test. However, using an 
identical laboratory method in paper II, we detected HPV in 97% of cases diagnosed as CIN3+ 
in a laboratory Audit (141). So we consider misclassification due to technical issues being 
highly unlikely, but if true, the difference on prognosis with regard to tumor hrHPV status will 
be attenuated and towards the null.  
7.1.4.4 Incident and prevalent cervical cancer  
Due to absence of information on HPV infection at the time of HPV vaccination in paper IV, 
we were not able to distinguish incident cases (HPV- naïve at the time of vaccination) and 
prevalent (prior HPV infection by time of vaccination) cervical cancer cases. As the HPV 
vaccines in use does not have therapeutic effect for the existing HPV infection (142, 143), 
inabilities to distinguish prevalent and incident cervical cancer cases in the vaccinated group 
will result in an underestimation of the effectiveness of HPV vaccination, especially for prior 
infection of HPV16/18. Therefore, we introduced a buffer period by adding a lag time after the 
first dose of vaccination to account for the prevalent cases, and minimize the bias of our 
estimation (Supplementary table S3 in paper IV). 
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7.1.5 Generalizability 
Generalizability, also called external validity, measures to which extent findings could be 
applicable to other settings. Among all findings in this thesis, results on screening and reduced 
risk of ASC and RICC should be able to generalize to most countries with screening programs. 
However, because the sensitivity of the cytology test can vary by country (144), our results on 
magnitude of risk reduction might only be applicable in certain countries with organized 
screening programs, comparable quality of cytology and clinical management. Similarly, the 
absolute value of PPV of cytology for CIN2+ should be generalized with caution, accounting 
for the sensitivity of cytology. However, we provided a measure of PPV change on a relative 
scale by age at vaccination initiation, which to some extent increased the generalizability. 
Besides, effectiveness of the HPV vaccination against cervical cancer can be relevant to all 
countries with HPV vaccination programs. Considering we have only followed women up to 
age 31, the current effectiveness can only be generalized to younger women. Last but not least, 
prognostic utility of tumor hrHPV status for prognosis of cervical cancer should be possible to 
generalize in a wider range of settings, regardless of whether the association is actually causal, 
or whether hrHPV status is a proxy for incompletely known but relevant tumor biology. 
7.2 INTERPRETATION AND IMPLICATIONS 
7.2.1 Cervical screening and risk of adenosquamous cell carcinoma and rare 
invasive cervical carcinoma. 
We found that routinely attending cervical screening could significantly reduce the risk of both 
ASC and RICC, and the risk reduction was more pronounced for women who had two 
screening tests during the last two recommended screening intervals than women who had only 
one test in one of the two recommended intervals. This finding highlighted the importance of 
attending cervical screening regularly and adhering to the recommended intervals to acquire 
benefits of preventing ASC and RICC. Meanwhile, the attenuated risk reduction for RICC 
compared to ASC in women who had similar screening attendance might reflect 1) distinctive 
rapid progression of RICC and 2) RICC were more likely to be preceded by glandular lesions 
which increased the difficulties of sampling because they located in the endocervical canal. 
Subsequently, the probabilities of detecting abnormal cells in screening with cytology reduced. 
Considering the aggressiveness of those types of cervical cancer, one could argue that highly 
aggressive cancers (especially RICC) are not expected to have precursors, and therefore might 
not fulfil screening criteria (145). We, however, showed that there was a risk reduction for both 
ASC and RICC through cervical screening. The risk reduction for ASC and RICC attributed to 
cervical screening is comparable to squamous cell carcinoma and adenocarcinoma (Table 7.1). 
The risk reduction of ASC is similar to squamous cell carcinoma, and the magnitude of risk 
reduction is slightly less for RICC and adenocarcinoma. This indicates that there is likely a 
precursor stage for most ASC and RICC, and therefore, can be prevented by cervical screening.  
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Table 7.1 Incidence rate ratios (IRR) of cervical carcinoma by screening status and 
histological types. Supplementary table F in paper I. 
Screening status 
SCC (n=2902) AC (n=766) ASC (n=155) RICC (n=152) 
IRR
a
 (95% CI) IRR
a
 (95% CI) IRR
a
 (95% CI) IRR
a
 (95% CI) 
No test Ref Ref Ref Ref 
One Test 0.43 (0.39 - 0.47) 0.88 (0.71 - 1.08) 0.39 (0.26 - 0.59) 0.69 (0.45 - 1.06) 
Two tests 0.19 (0.17 - 0.21) 0.57 (0.46 - 0.71) 0.22 (0.14 - 0.34) 0.34 (0.21 - 0.55) 
SCC: squamous cell carcinoma; AC: adenocarcinoma; ASC: adenosquamous cell carcinoma; RICC: rare types 
of invasive cervical carcinoma. Only women age 30 and above were included. .a Incidence rate ratio adjusted by 
education level and age. Data for SCC and AC adapted from Wang et al, IJC 2019 (55). 
A stronger magnitude of risk reduction from having two tests was observed and the results 
confirmed the commonly accepted fact that repeat testing could potentially increase the 
sensitivity of cytology. For women who had two normal tests in the last two recommended 
screening intervals, a very low risk of ASC and RICC was demonstrated. In contrast, the higher 
risk of ASC and RICC after having at least one abnormal test could be due to inadequate 
clinical management, in addition to lower sensitivity of cytology for glandular cells. A previous 
publication based on the nationwide Audit in Sweden showed that women who had abnormal 
cytology but without a follow-up biopsy was associated with 89% significantly increased risk 
of cervical cancer compared to those who had follow-up biopsies (32). Moreover, it might also 
reflect that the current management strategies might need improvement for certain abnormal 
cytology (ie. atypia glandular cells) (146, 147).  
Considering that the majority of ASC and RICC were positive for hrHPV, with HPV18 as the 
dominant type, we could expect that most of the ASC and RICC can be prevented through HPV 
vaccination. HPV testing has been shown to detect early precancerous lesions, but how the 
HPV testing will influence ASC and RICC is still to be investigated. The established 
nationwide cervical cancer Audit framework in paper I using a nested case-control study design 
could serve as a standard for evaluation of cervical cancer screening. This should also be 
applicable to countries without information on cervical screening readily available. 
7.2.2 Tumor high-risk HPV status and prognosis of invasive cervical cancer. 
Women who had hrHPV-positive tumors were associated with better prognosis of cervical 
cancer compared to women who had hrHPV-negative tumors. Of note, hrHPV-negativity in 
the tumor does not necessarily mean that hrHPV has not been involved during the development 
of cervical cancer. On the contrary, hrHPV-negativity in representative tumor tissue might 
indicates the loss of hrHPV-expression during the carcinogenic process in a subset of women. 
A previous study showed that the proportion of HPV-negative tumors increased among women 
diagnosed at an older age and more advanced stage (148), which was also confirmed in our 
data. However, the tumor biology of how the loss or integration of hrHPV may occur, and the 
mechanisms for why women who had hrHPV-positive tumors showed better prognosis 
compared to women who had hrHPV-negative tumors is not completely clear.  
  39 
The hrHPV-negative cancers may have been immortalized and lost internal mutation control. 
This might have progressed to the point of acquiring significant somatic host mutational 
burden, which is connected to malignant potential for growth and spread. More work is needed 
to further elucidate potential detailed explanations and mechanisms. According to the current 
evidence on HPV and the prognosis of oropharyngeal cancer, HPV-positive cancers could be 
more immunogenic due to the presence of viral proteins, so the tumors could become more 
susceptible to the immune system and be better controlled (149). One could speculate that this 
is also the case for hrHPV-positive cervical cancer.  
Although our data in this study was not able to provide constructive explanations to this 
biological phenomenon, we suggested a significant association between detection of hrHPV in 
tumor tissue and prognosis of cervical cancer. The difference in prognosis between hrHPV-
positive cases and hrHPV-negative cases was robust and independent of age at cancer 
diagnosis, FIGO stage, and histological types. Current laboratory methods in HPV genotyping 
and testing for tumor hrHPV status could possibly provide extra insights beyond the currently 
established clinical prognostic factors. 
7.2.3 Screening performance of cytology test among HPV-vaccinated 
cohorts. 
The lower PPV for CIN2+ in vaccinated compared to unvaccinated women among birth 
cohorts that were partially vaccinated through either subsidized opportunistic or free-of-charge 
catch-up vaccination confirmed earlier findings from simulation studies that PPV was predicted 
to decrease when the prevalence of cervical lesions declined (91, 94). Therefore, it is not 
surprising to see a lower PPV among girls who initiated vaccination before 17, which is well 
in line with what the protection of the HPV vaccine confers. Our findings highlighted that the 
PPV for the screening program did not only depend on vaccine coverage in the respective birth 
cohort, but also relied on the proportion of individuals vaccinated at young age - an important 
factor to be accounted for when considering changing of screening strategies in real-life. 
The vaccination coverage has increased substantially among younger birth cohorts in Sweden. 
Over 80% of females in birth cohorts 1999 onwards were vaccinated (70). With a coverage 
over 50% in girls, the birth cohorts should also benefit from a herd-immunity effect (90), 
leading to a very low prevalence of cervical lesions in that population. Consequently, a very 
low PPV of cytology for CIN2+ could be expected, when the younger birth cohorts enter the 
screening program. 
Given the proven effectiveness of the HPV vaccines, HPV16/18-related lesions in highly 
vaccinated birth cohorts would also be expected to be less common, and possibly with an 
increased load of low-grade cytology caused by non-oncogenic HPV types. As we saw, the 
PPV of low-grade cytology for CIN2+ also declined in the vaccinated population. A pragmatic 
adaptation of the screening strategies will be needed and should account for shifts vaccination 
coverage by cohort. HPV16/18 positivity at first screening among highly vaccinated cohorts 
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could serve as an indication of persistent infection with HPV16/18 (an infection acquired 
before HPV vaccination), therefore HPV-based screening with genotyping might be an 
alternative in achieving better performance. 
7.2.4 HPV vaccination and risk of invasive cervical cancer. 
The ultimate goal of HPV vaccination is to prevent invasive cervical cancer. We are, to date, 
the first to show HPV vaccination could effectively reduce the risk of invasive cervical cancer 
among vaccinated women compared to unvaccinated women, based on a nationwide real-life 
vaccination program. The results were in line with available data including a promising clinical 
trial (150) which reported no detection of HPV-related cancer cases after HPV vaccination, and 
an ecological study from US (151) that showing a decreased cervical cancer incidence among 
young women after implementation of HPV vaccination.   
In the assessment of comparing age at vaccination initiation with regard to incidence of cervical 
cancer, a more pronounced protection against cervical cancer was seen among women initiating 
vaccination before age 17. This finding emphasized the benefits of administrating HPV 
vaccination at younger age in order to achieve good protection and greater effectiveness. The 
incubation time from HPV infection to occurrence of cervical cancer usually takes 5 to 20 years 
(25). As we have only been able to assess the incidence of cervical cancer among women up 
to age 30, the effectiveness of HPV vaccination derived from our data might mainly imply the 
effectiveness of HPV vaccination against fast-growing tumors among young women.  
In our population, only part of the birth cohorts included (1993 onwards) achieved a coverage 
above 50%, the threshold for achieving a herd-immunity effect (90). However, with an 
interaction analysis, we did not detect any herd effect in the current population. This could 
possibly be due to the relatively short follow-up for the younger birth cohorts as they have not 
yet been followed up to the age at which the incidence of cervical cancer increases. With that 
being said, considering herd effects is essential in future evaluations of long-term effectiveness 
of HPV vaccination, especially in birth cohorts vaccinated at young ages and with high vaccine 
coverage. Otherwise, the effectiveness of HPV vaccination would be underestimated. 
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8 CONCLUSION 
With the included papers in this thesis, a few conclusions could be noted: 
 Cervical screening was associated with a substantially decreased risk of both ASC and 
RICC, and the risk reduction derived from screening was attenuated for RICC 
compared to ASC. The majority of ASC and RICC tumor tissues were positive for 
high-risk HPV. The evidence provides a benchmark for evaluation of future cervical 
screening strategies (paper I). 
 
 hrHPV status in cervical tumor tissues was associated with prognosis of invasive 
cervical cancer. Women with hrHPV-positive cervical tumors showed a significantly 
better prognosis than women with hrHPV-negative tumors, and the difference was 
independent of age, FIGO stage, and histological type. Rountinely testing HPV 
genotypes in cervical tumors could add value to the clinically established prognositic 
factors (paper II). 
 
 PPV of cytology for CIN2+ decreased among women who had HPV vaccination, and 
the the maximum reduction was seen among women vaccinated before age 17 followed 
by women vaccinated at age 17-22. A continued decrease of PPV in cytology-based 
screening could be expected, especially among highly vaccinated birth cohorts, which 
points towards the need to re-evaluate screening methods and requirements for the 
young and vaccinated population (paper III). 
 
 Effectiveness of HPV vaccination against invasive cervical cancer in a nationwide 
population vaccinated through a real-life program was demonstrated. HPV vaccination 
is associated with lower risk of invasive cervical cancer at population level. (paper IV). 
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9 FUTURE PERSPECTIVES 
Globally, there were approximately 570,000 newly diagnosed cervical cancer cases and 
311,000 deaths that occurred in 2018 (152). In May 2018, WHO called for the elimination of 
cervical cancer as a public health problem (age-adjusted incidence rate below four per 100,000 
women-years) within this century (19). Australia has been predicted to eliminate cervical 
cancer by 2028, if the current primary HPV screening and HPV vaccination maintained (153). 
Recently, WHO has proposed a draft of global strategy with “90-70-90 target” (90% girls fully 
vaccinated before age 15, 70% women screened at age 35-45, and 90% women treated for 
cervical diseases) by 2030 for countries on their path towards elimination of cervical cancer 
(154). Modelling studies showed that achieving the target is expected to significantly prevent 
deaths and reach the goal of elimination of cervical cancer in low- and middle- income 
countries within the next century (155, 156). Therefore, a chief goal in the future should be to 
minimize the disparities between high-income and low- and middle- income countries, and to 
scale-up the coverage of preventive strategies globally. 
This thesis addresses a range of research questions on the role of HPV, HPV vaccination, and 
cervical screening. HPV primary screening has been gradually implemented in many countries. 
Our findings on cervical screening with cytology and the reduced risk of ASC and RICC set a 
benchmark for future evaluation on organized screening program, especially after the transition 
from cytology screening to primary HPV screening. A regular monitoring and evaluation 
would allow us to ensure the quality of organized screening program, and to identify the issues 
for further improvement. Despite that a negative HPV test provides greater reassurance against 
CIN2+, primary HPV screening has its own challenges. Women who had HPV-positive test 
results usually receive a triage test to ensure those having transient HPV infection will not be 
referred to colposcopy. The current triage methods are mainly partially HPV genotyping and 
cytology, and other options such as p16/Ki-67 dual stain cytology and methylation are also 
under consideration (157). What will be the optimal triage method under the current screening 
strategy to allow quick stratification of women at different risk levels needs further 
investigation. An effective triage method could help to avoid unnecessary referral and 
treatment, which might result in harms (e.g. adverse pregnancy outcomes) from screening. 
In Sweden, HPV vaccination was introduced more than 10 years ago and with demonstrated 
population impact. In the short-term, HPV genotyping of HPV-vaccinated cancer cases to 
understand reasons for the occurrence of those cancers is needed. A follow-up study to 
investigate the long-term effectiveness of HPV vaccination against cervical cancer would be 
essential, and it could also provide more insights on the duration of protection from HPV 
vaccines. Effectiveness of HPV vaccination with regard to number of doses will also be of 
great value in enhancing the cost-effectiveness of the vaccination program. Together with the 
gender-neutral vaccination program, which has been implemented in certain countries and soon 
will be in Sweden, evaluation on herd effects and monitoring the HPV genotypes circulating 
in the populations could also be strategically important. Besides, a regular surveillance of 
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adverse events after HPV vaccination is important to ensure the long-term safety profile of 
HPV vaccination, and also strengthen the public confidence in the vaccination program. 
Furthermore, with improving vaccination coverage and changing HPV prevalence in the 
population due to highly effective vaccines, reconsidering screening methods for vaccinated 
cohorts, and the target age of starting screening are crucial questions to consider. In Australia, 
HPV screening has been used as primary screening for birth cohorts where the majority 
received vaccination, and it seems that HPV primary screening would be more optimal than 
cytology for highly vaccinated cohorts. A pilot study of using primary HPV screening among 
women under 30 will be implemented in Sweden later this year. With the development of 
personalized medicine, will risk stratified personalized screening be applicable? There are lots 
of work ongoing and upcoming results to look forward to.  
Although the benefits from HPV vaccination and screening are demonstrated, and a high 
coverage of HPV vaccination (over 80% for at least one dose in the school-based program) and 
screening (over 80% coverage for one screening interval) is documented in Sweden, we should 
note that there is potentially a group of women who have not participated in either of these 
preventive procedures. According to the current guidelines, vaccinated women are 
recommended to attend screening. Previous studies also demonstrated that vaccinated women 
had equivalent or higher screening attendance than unvaccinated women from the opportunistic 
and catch-up program (139, 140). In the coming years, an updated investigation on screening 
attendance by vaccination status is warranted to gain further insights on how to promote the 
coverage of cervical cancer prevention programs. 
Last, yet importantly, there has been a heated debate on HPV-negative cervical cancer in recent 
years. We have shown that tumor hrHPV status could be a potential biomarker for prognosis 
of cervical cancer, especially when HPV testing has become routinely available. How to 
integrate this information clinically to support the decision-making in treatment could be 
further investigated. Besides, it would be very interesting to verify the HPV genotyping results 
based on fresh tumor tissues, and also link to their previous HPV screening results given that 
information is routinely collected through NKCx, and more and more counties are introducing 
HPV screening. This could provide insights on 1) whether HPV-negative cervical cancer was 
HPV-positive at some point during the screening, which we believe the answers to be yes 2) 
when and how the HPV causing cervical cancer is lost during carcinogenesis, and subsequently 
influences the prognosis. 
This thesis contributes evidence in prevention and prognosis of cervical cancer. With HPV 
vaccination, cervical screening and treatment of precancerous lesions, cervical cancer could be 
eliminated. Efforts in minimizing the disparities in accessing healthcare resources, improving 
and maintaining a good coverage of preventive strategies at global level are required. 
Eventually, cervical cancer would be eliminated as a public health problem. 
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